Silexion Therapeutics Corp宣布,计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外,公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。
Silexion Therapeutics Corp宣布,计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外,公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.